Journal Home
Search for

Volume 27, Issue 5, Pages 338-343 (September 2005)


View previous. 6 of 14 View next.

Telephonic case-finding of major depression in a Medicaid chronic disease management program for diabetes and heart failure

Ronald T. Ackermann, M.D., M.P.H.aCorresponding Author Informationemail address, Marc B. Rosenman, M.D.bc, Stephen M. Downs, M.D., M.S.bc, Ann M. Holmes, Ph.D.d, Barry P. Katz, Ph.D.a, Jingjin Li, Ph.D.ab, Alan J. Zillich, Pharm.D.abe, Caroline P. Carney, M.D., M.Sc.abf, Thomas S. Inui, M.D., Sc.M.ab

Received 17 March 2005; accepted 17 May 2005.

Abstract 

Objective

Major depression is common in low-income and chronically ill persons and is a barrier for effective chronic disease care. We evaluated a Medicaid-sponsored strategy for detecting depressive symptoms in adults with diabetes or congestive heart failure.

Methods

Using a two-item screening tool, 890 adults enrolled in the Indiana Chronic Disease Management Program were assessed by telephone for depressive symptoms between December 2003 and March 2004. A subset of 386 participants also completed the eight-item Patient Health Questionnaire (PHQ-8) depression measure. Antidepressant use was examined using pharmacy claims.

Results

Depressed mood or anhedonia was reported by 51% of participants. About one in four participants had a PHQ-8 score indicating a high risk for major depression (score ≥10). The two-item screen was 96% sensitive [95% confidence interval (CI), 89–99%] and 60% specific (95% CI, 54–65%) for identifying members at high risk for depression by the full PHQ-8 instrument. Only half of participants with high-risk PHQ-8 scores had a pharmacy claim indicating that an antidepressant medication was filled within 120 days of the depression screening.

Conclusions

A two-stage, telephonic approach involving the PHQ-8 instrument for Medicaid members with either depressed mood or anhedonia could identify two clinically depressed persons for every nine members screened.

a Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA

b Regenstrief Institute, Inc., Indianapolis, IN 46202, USA

c Department of Pediatrics, Children's Health Services Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA

d School of Public and Environmental Affairs, Indiana University Purdue University, Indianapolis, IN 46202, USA

e Department of Pharmacy Practice, Purdue University School of Pharmacy and Pharmaceutical Sciences, Indianapolis, IN 46202, USA

f Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN 46202, USA

Corresponding Author InformationCorresponding author. 250 University Boulevard Suite 122; Indianapolis, IN 46202, USA. Tel.: +1 317 278 0906; fax: +1 317 278 0911.

PII: S0163-8343(05)00073-3

doi:10.1016/j.genhosppsych.2005.05.009


View previous. 6 of 14 View next.